ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0390

Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry

Flavia Castelino1, John VanBuren2, Emily Startup2, Shervin Assassi3, Elana Bernstein4, Lorinda Chung5, Chase Correia6, Luke Evnin7, Tracy Frech8, Jessica Gordon9, Faye Hant10, Laura Hummers11, Dinesh Khanna12, Nora Sandorfi13, Ami Shah14, Victoria Shanmugam15 and Virginia Steen16, 1Massachusetts General Hospital/Harvard Medical School, Boston, MA, 2University of Utah, Salt Lake City, UT, 3University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 4Columbia University, New York, NY, 5Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, 6Northwestern University, Chicago, IL, 7Scleroderma Research Foundation, Brisbane, CA, 8University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 9Hospital for Special Surgery, New York, NY, 10Medical University of South Carolina, Charleston, SC, 11Johns Hopkins Univerisity, Ellicott City, MD, 12University of Michigan, Ann Arbor, MI, 13University of Pennsylvania, Philadelphia, PA, 14Johns Hopkins University School of Medicine, Ellicott City, MD, 15The George Washington University, Washington, DC, 16Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC

Meeting: ACR Convergence 2020

Keywords: registry, Scleroderma, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in SSc. Several international observational studies have evaluated characteristics of ILD in their SSc patient populations, however these studies do not necessarily reflect the US SSc patient population. The purpose of this analysis was to assess the baseline characteristics of SSc patients with and without restrictive lung disease (RLD) in a US based longitudinal registry.

Methods: The Collaborative National Quality and Efficacy Registry (CONQUER) for Systemic Sclerosis is a multicenter US based registry of patients with early SSc within 5 years of first non-Raynaud’s symptom enrolled at 13 expert centers. All patients are >18 years old and fulfill the 2013 ACR/EULAR Classification Criteria for SSc. All patients who had a pulmonary function test (PFT) at baseline on or before April 1, 2020 were included in this analysis. As a high-resolution computed tomography (HRCT) Chest at baseline was not available to characterize ILD for all patients, patients were characterized as RLD based on force vital capacity (FVC) % predicted < 80% or total lung capacity (TLC) % predicted < 80%. Chi-squared test and Fisher’s Exact test were performed for categorical variables. T-test was performed for continuous variables. Multivariable modeling with stepwise selection was performed to predict RLD.  A p-value < 0.05 was considered significant.

Results: 329 patients underwent PFTs at baseline with 147 (45%) patients characterized as RLD. There was no significant difference in age, sex or disease duration between patients with and without RLD. Patients with RLD had a mean disease duration of 2.6 years and a mean FVC of 67% at baseline. RLD patients compared to no RLD were more likely to be non-white (African American, Asian or other) and have diffuse disease, a higher modified Rodnan skin score, digital pitting scars and abnormal GI symptoms including gastric antral vascular ectasia (GAVE), esophageal dysmotility, small bowel dysfunction or malabsorption (Table 1).  RLD patients who underwent HRCT also were more likely to have a patulous esophagus on HRCT compared to those patients without RLD (Table 2). In multivariable analysis, non-white race, crackles on exam, DLCO< 60%, and higher physician global health assessment scores were found to be independently associated with RLD (Table 3).

Conclusion: We found that SSc patients with RLD enrolled in CONQUER had more diffuse disease and significant GI manifestations compared to patients without RLD. Non-white race was independently associated with RLD.  Interestingly, patients with RLD had early disease yet already significant restrictive defects on PFTs, suggesting that even earlier detection methods are necessary. Further investigation into the factors associated with ILD and its progression is warranted as we collect long-term prospective data on this growing cohort of US SSc patients.

Table 1

Table 2

Table 3


Disclosure: F. Castelino, Boehringer Ingelheim, 5, 8; J. VanBuren, None; E. Startup, None; S. Assassi, Momenta, 1, corbus, 1, Integrity Continuing Education, 1, Boehringer Ingelheim, 1, 2, 3; E. Bernstein, None; L. Chung, Eicos, 1, Reata, 1, Boehringer Ingelheim, 1, 2, Mitsubishi Tanabe, 1; C. Correia, None; L. Evnin, MPM Capital, 4, 9, Civi Biopharma, 1; T. Frech, None; J. Gordon, None; F. Hant, None; L. Hummers, Corbus Pharmaceuticals, 1, 2, Boehringer Ingelheim, 1, 2, CSL Behring, 1, 2, Cumberland Pharmaceuticals, 1, Medpace, 1, Glaxo Smith Kline, 1, Kadmon Corporation, 1; D. Khanna, Bayer, 2, BMS, 2, Horizon, 2, Pfizer, 2, NIH, 2, Immune Tolerance Network, 2, Eicos Sciences Inc, 4, Acceleron,, 5, Actelion,, 5, Abbvie,, 5, Amgen,, 5, Bayer,, 5, Boehringer Ingelheim, 5, CSL Behring, 5, Corbus,, 5, Galapagos,, 5, Genentech/Roche, 5, GSK, 5, Horizon, 5, Merck,, 5, Mitsubishi Tanabe Pharma, 5, Sanofi-Aventis, 5, United Therapeutics, 5, Impact PH, 9, Scleroderma Development, 6, CiviBioPharma/Eicos Sciences Inc, 6; N. Sandorfi, None; A. Shah, None; V. Shanmugam, None; V. Steen, Boehringer Ingelheim, 2, 5, corbus, 2, 5, eicos, 2, 5, genetech, 2, forbius, 5, galapagos, 5.

To cite this abstract in AMA style:

Castelino F, VanBuren J, Startup E, Assassi S, Bernstein E, Chung L, Correia C, Evnin L, Frech T, Gordon J, Hant F, Hummers L, Khanna D, Sandorfi N, Shah A, Shanmugam V, Steen V. Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/baseline-characteristics-of-systemic-sclerosis-ssc-patients-with-restrictive-lung-disease-in-a-multi-center-united-states-based-longitudinal-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-characteristics-of-systemic-sclerosis-ssc-patients-with-restrictive-lung-disease-in-a-multi-center-united-states-based-longitudinal-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology